Number of Participants With Symptomatic Adverse Effects as Measured by the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) · Source last updated 2026-07-01
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to approximately 263 weeks
What was measured
PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. It includes symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting, watery eyes, cough, itchy, loose/watery stools, Numb/Tingling Hands/Feet (N/T H/F), Pain/Burning (P/B) and Problems Tasting Food/Drink (Prob Tasting F/D) . Items are scored individually on a 0 to 4 scale for severity, frequency and interference. A score of 0 indicates no symptom or interference, while higher score of 4 signify increasing severity, frequency, and interference with daily activities.
Analysis population: ITT Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories.
Groups in this outcome
Belantamab Mafodotin
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
Pomalidomide Plus Dexamethasone
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
217
Pomalidomide Plus Dexamethasone
102
Reported measurements
Blurred Vision, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
40
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
31
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
50
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
32
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
50
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
21
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
43
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
8
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
24
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
67
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
10
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
167
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
63
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
167
Pomalidomide Plus Dexamethasone
63
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
167
Pomalidomide Plus Dexamethasone
63
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
46
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
31
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
167
Pomalidomide Plus Dexamethasone
63
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
38
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
167
Pomalidomide Plus Dexamethasone
63
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
40
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
167
Pomalidomide Plus Dexamethasone
63
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
29
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
167
Pomalidomide Plus Dexamethasone
63
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
69
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
10
Not reported
Not reported
Not reported
Not reported
Blurred Vision, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
167
Pomalidomide Plus Dexamethasone
63
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
153
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
56
Not reported
Not reported
Not reported
Not reported
Constipation, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
87
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
38
Not reported
Not reported
Not reported
Not reported
Constipation, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
62
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
22
Not reported
Not reported
Not reported
Not reported
Constipation, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
26
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
Constipation, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
20
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14
Not reported
Not reported
Not reported
Not reported
Constipation, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Constipation, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
32
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
Constipation, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
120
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
56
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
57
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
36
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
75
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
34
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
44
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
23
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
31
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
9
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
150
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
58
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
150
Pomalidomide Plus Dexamethasone
58
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
43
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
150
Pomalidomide Plus Dexamethasone
58
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
51
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
20
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
150
Pomalidomide Plus Dexamethasone
58
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
29
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
150
Pomalidomide Plus Dexamethasone
58
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
19
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
150
Pomalidomide Plus Dexamethasone
58
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
150
Pomalidomide Plus Dexamethasone
58
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
27
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
8
Not reported
Not reported
Not reported
Not reported
Decreased Appetite, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
150
Pomalidomide Plus Dexamethasone
58
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
107
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
41
Not reported
Not reported
Not reported
Not reported
Fatigue, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
19
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
8
Not reported
Not reported
Not reported
Not reported
Fatigue, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
50
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
21
Not reported
Not reported
Not reported
Not reported
Fatigue, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
77
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
35
Not reported
Not reported
Not reported
Not reported
Fatigue, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
42
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
19
Not reported
Not reported
Not reported
Not reported
Fatigue, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
19
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11
Not reported
Not reported
Not reported
Not reported
Fatigue, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
61
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
30
Not reported
Not reported
Not reported
Not reported
Fatigue, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
188
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
86
Not reported
Not reported
Not reported
Not reported
Fatigue, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
188
Pomalidomide Plus Dexamethasone
86
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Fatigue, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
188
Pomalidomide Plus Dexamethasone
86
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
46
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
26
Not reported
Not reported
Not reported
Not reported
Fatigue, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
188
Pomalidomide Plus Dexamethasone
86
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
64
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
25
Not reported
Not reported
Not reported
Not reported
Fatigue, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
188
Pomalidomide Plus Dexamethasone
86
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
44
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
Fatigue, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
188
Pomalidomide Plus Dexamethasone
86
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
25
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14
Not reported
Not reported
Not reported
Not reported
Fatigue, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
188
Pomalidomide Plus Dexamethasone
86
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
69
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
31
Not reported
Not reported
Not reported
Not reported
Fatigue, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
188
Pomalidomide Plus Dexamethasone
86
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
179
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
82
Not reported
Not reported
Not reported
Not reported
General Pain, Frequency, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
85
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
46
Not reported
Not reported
Not reported
Not reported
General Pain, Frequency, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
61
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
26
Not reported
Not reported
Not reported
Not reported
General Pain, Frequency, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
35
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16
Not reported
Not reported
Not reported
Not reported
General Pain, Frequency, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
17
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
General Pain, Frequency, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
General Pain, Frequency, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
26
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
General Pain, Frequency, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
122
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
48
Not reported
Not reported
Not reported
Not reported
General Pain, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
122
Pomalidomide Plus Dexamethasone
48
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
General Pain, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
122
Pomalidomide Plus Dexamethasone
48
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
59
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
26
Not reported
Not reported
Not reported
Not reported
General Pain, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
122
Pomalidomide Plus Dexamethasone
48
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
28
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15
Not reported
Not reported
Not reported
Not reported
General Pain, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
122
Pomalidomide Plus Dexamethasone
48
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
General Pain, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
122
Pomalidomide Plus Dexamethasone
48
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
General Pain, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
122
Pomalidomide Plus Dexamethasone
48
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
21
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
General Pain, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
122
Pomalidomide Plus Dexamethasone
48
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
108
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
45
Not reported
Not reported
Not reported
Not reported
General Pain, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
108
Pomalidomide Plus Dexamethasone
45
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
22
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15
Not reported
Not reported
Not reported
Not reported
General Pain, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
108
Pomalidomide Plus Dexamethasone
45
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
50
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
18
Not reported
Not reported
Not reported
Not reported
General Pain, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
108
Pomalidomide Plus Dexamethasone
45
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
19
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
10
Not reported
Not reported
Not reported
Not reported
General Pain, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
108
Pomalidomide Plus Dexamethasone
45
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
General Pain, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
108
Pomalidomide Plus Dexamethasone
45
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
General Pain, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
108
Pomalidomide Plus Dexamethasone
45
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
17
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
General Pain, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
108
Pomalidomide Plus Dexamethasone
45
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
86
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
30
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
132
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
58
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
44
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
20
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
22
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
75
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
36
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
75
Pomalidomide Plus Dexamethasone
36
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
23
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
75
Pomalidomide Plus Dexamethasone
36
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
33
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
75
Pomalidomide Plus Dexamethasone
36
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
75
Pomalidomide Plus Dexamethasone
36
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
75
Pomalidomide Plus Dexamethasone
36
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
75
Pomalidomide Plus Dexamethasone
36
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
Mouth/Throat Sores, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
75
Pomalidomide Plus Dexamethasone
36
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
52
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
21
Not reported
Not reported
Not reported
Not reported
Nausea, Frequency, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
97
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
54
Not reported
Not reported
Not reported
Not reported
Nausea, Frequency, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
54
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
23
Not reported
Not reported
Not reported
Not reported
Nausea, Frequency, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
32
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
Nausea, Frequency, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
17
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Nausea, Frequency, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Nausea, Frequency, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
24
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Nausea, Frequency, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
110
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
40
Not reported
Not reported
Not reported
Not reported
Nausea, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
8
Not reported
Not reported
Not reported
Not reported
Nausea, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
55
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
19
Not reported
Not reported
Not reported
Not reported
Nausea, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
26
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
9
Not reported
Not reported
Not reported
Not reported
Nausea, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
17
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Nausea, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Nausea, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
19
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Nausea, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
110
Pomalidomide Plus Dexamethasone
40
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
100
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
32
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Frequency, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
127
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
74
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Frequency, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
51
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Frequency, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
20
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Frequency, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Frequency, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Frequency, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Frequency, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
80
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
20
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
80
Pomalidomide Plus Dexamethasone
20
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
80
Pomalidomide Plus Dexamethasone
20
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
46
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
80
Pomalidomide Plus Dexamethasone
20
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
80
Pomalidomide Plus Dexamethasone
20
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
80
Pomalidomide Plus Dexamethasone
20
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
80
Pomalidomide Plus Dexamethasone
20
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Nosebleeds, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
80
Pomalidomide Plus Dexamethasone
20
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
68
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Frequency, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
102
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
43
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Frequency, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
52
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
25
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Frequency, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
34
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Frequency, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
17
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Frequency, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Frequency, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
19
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Frequency, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
105
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
51
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
105
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
11
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
105
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
59
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
23
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
105
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
25
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
105
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
9
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
10
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
105
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
105
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11
Not reported
Not reported
Not reported
Not reported
Shivering/Shaking Chills, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
105
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
94
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
45
Not reported
Not reported
Not reported
Not reported
Shortness of Breath, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
66
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
24
Not reported
Not reported
Not reported
Not reported
Shortness of Breath, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
68
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
32
Not reported
Not reported
Not reported
Not reported
Shortness of Breath, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
45
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
22
Not reported
Not reported
Not reported
Not reported
Shortness of Breath, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
20
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
9
Not reported
Not reported
Not reported
Not reported
Shortness of Breath, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Shortness of Breath, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
28
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16
Not reported
Not reported
Not reported
Not reported
Shortness of Breath, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
141
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
70
Not reported
Not reported
Not reported
Not reported
Vomiting, Frequency, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
158
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
81
Not reported
Not reported
Not reported
Not reported
Vomiting, Frequency, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
27
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Vomiting, Frequency, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
12
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Vomiting, Frequency, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Vomiting, Frequency, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
0
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Vomiting, Frequency, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Vomiting, Frequency, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
49
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
Vomiting, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
13
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Vomiting, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
13
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
23
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
Vomiting, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
13
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
Vomiting, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
13
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Vomiting, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
13
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Vomiting, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
13
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
7
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Vomiting, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
49
Pomalidomide Plus Dexamethasone
13
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
44
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
76
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
41
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
60
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
39
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
42
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
27
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
2
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
29
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
131
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
53
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
131
Pomalidomide Plus Dexamethasone
53
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
15
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
131
Pomalidomide Plus Dexamethasone
53
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
61
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
27
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
131
Pomalidomide Plus Dexamethasone
53
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
32
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
131
Pomalidomide Plus Dexamethasone
53
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
131
Pomalidomide Plus Dexamethasone
53
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
131
Pomalidomide Plus Dexamethasone
53
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
23
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Watery Eyes, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
131
Pomalidomide Plus Dexamethasone
53
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
116
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
37
Not reported
Not reported
Not reported
Not reported
Cough, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
103
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
43
Not reported
Not reported
Not reported
Not reported
Cough, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
69
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
28
Not reported
Not reported
Not reported
Not reported
Cough, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
17
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16
Not reported
Not reported
Not reported
Not reported
Cough, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
15
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
Cough, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
Cough, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Cough, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
104
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
51
Not reported
Not reported
Not reported
Not reported
Cough, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
32
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
16
Not reported
Not reported
Not reported
Not reported
Cough, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
44
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
18
Not reported
Not reported
Not reported
Not reported
Cough, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
20
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
10
Not reported
Not reported
Not reported
Not reported
Cough, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Cough, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Cough, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
8
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
7
Not reported
Not reported
Not reported
Not reported
Cough, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
104
Pomalidomide Plus Dexamethasone
51
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
72
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
35
Not reported
Not reported
Not reported
Not reported
Itchy, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
98
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
52
Not reported
Not reported
Not reported
Not reported
Itchy, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
75
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
24
Not reported
Not reported
Not reported
Not reported
Itchy, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
24
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
15
Not reported
Not reported
Not reported
Not reported
Itchy, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
6
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Itchy, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
0
Not reported
Not reported
Not reported
Not reported
Itchy, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
Itchy, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
109
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
42
Not reported
Not reported
Not reported
Not reported
Loose/Watery Stools, Frequency, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
86
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
40
Not reported
Not reported
Not reported
Not reported
Loose/Watery Stools, Frequency, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
48
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
27
Not reported
Not reported
Not reported
Not reported
Loose/Watery Stools, Frequency, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
37
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
14
Not reported
Not reported
Not reported
Not reported
Loose/Watery Stools, Frequency, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
22
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
9
Not reported
Not reported
Not reported
Not reported
Loose/Watery Stools, Frequency, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
14
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Loose/Watery Stools, Frequency, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
36
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
13
Not reported
Not reported
Not reported
Not reported
Loose/Watery Stools, Freq., Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
121
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
54
Not reported
Not reported
Not reported
Not reported
N/T H/F, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
50
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
26
Not reported
Not reported
Not reported
Not reported
N/T H/F, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
70
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
25
Not reported
Not reported
Not reported
Not reported
N/T H/F, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
54
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
31
Not reported
Not reported
Not reported
Not reported
N/T H/F, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
23
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
11
Not reported
Not reported
Not reported
Not reported
N/T H/F, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
N/T H/F, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
33
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
N/T H/F, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
157
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
68
Not reported
Not reported
Not reported
Not reported
N/T H/F, Interference, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
157
Pomalidomide Plus Dexamethasone
68
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
34
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
12
Not reported
Not reported
Not reported
Not reported
N/T H/F, Interference, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
157
Pomalidomide Plus Dexamethasone
68
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
57
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
27
Not reported
Not reported
Not reported
Not reported
N/T H/F, Interference, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
157
Pomalidomide Plus Dexamethasone
68
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
43
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
20
Not reported
Not reported
Not reported
Not reported
N/T H/F, Interference, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
157
Pomalidomide Plus Dexamethasone
68
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
13
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
5
Not reported
Not reported
Not reported
Not reported
N/T H/F, Interference, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
157
Pomalidomide Plus Dexamethasone
68
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
10
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
N/T H/F, Interference, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
157
Pomalidomide Plus Dexamethasone
68
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
23
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
9
Not reported
Not reported
Not reported
Not reported
N/T H/F, Interference, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
157
Pomalidomide Plus Dexamethasone
68
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
123
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
56
Not reported
Not reported
Not reported
Not reported
P/B Urination, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
135
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
68
Not reported
Not reported
Not reported
Not reported
P/B Urination, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
49
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
17
Not reported
Not reported
Not reported
Not reported
P/B Urination, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
P/B Urination, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
4
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
2
Not reported
Not reported
Not reported
Not reported
P/B Urination, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
1
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
1
Not reported
Not reported
Not reported
Not reported
P/B Urination, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
5
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
3
Not reported
Not reported
Not reported
Not reported
P/B Urination, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
72
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
26
Not reported
Not reported
Not reported
Not reported
Prob Tasting F/D, Severity, 0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
108
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
51
Not reported
Not reported
Not reported
Not reported
Prob Tasting F/D, Severity, 1
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
57
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
24
Not reported
Not reported
Not reported
Not reported
Prob Tasting F/D, Severity, 2
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
24
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
9
Not reported
Not reported
Not reported
Not reported
Prob Tasting F/D, Severity, 3
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
15
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
6
Not reported
Not reported
Not reported
Not reported
Prob Tasting F/D, Severity, 4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
3
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
4
Not reported
Not reported
Not reported
Not reported
Prob Tasting F/D, Severity, 3+4
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
18
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
10
Not reported
Not reported
Not reported
Not reported
Prob Tasting F/D, Severity, Any Scale >0
Analysis denominator · Participants
Group
Source count
Belantamab Mafodotin
207
Pomalidomide Plus Dexamethasone
94
Values in Participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Belantamab Mafodotin
99
Not reported
Not reported
Not reported
Not reported
Pomalidomide Plus Dexamethasone
43
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
40
group Id
OG001
value
31
denoms
counts
group Id
OG000
value
207
group Id
OG001
value
94
units
Participants
title
Blurred Vision, Severity, 0
categories
measurements
group Id
OG000
value
50
group Id
OG001
value
32
denoms
counts
group Id
OG000
value
207
group Id
OG001
value
94
units
Participants
title
Blurred Vision, Severity, 1
categories
measurements
group Id
OG000
value
50
group Id
OG001
value
21
denoms
counts
group Id
OG000
value
207
group Id
OG001
value
94
units
Participants
title
Blurred Vision, Severity, 2
categories
measurements
group Id
OG000
value
43
group Id
OG001
value
8
denoms
counts
group Id
OG000
value
207
group Id
OG001
value
94
units
Participants
title
Blurred Vision, Severity, 3
categories
measurements
group Id
OG000
value
24
group Id
OG001
value
2
denoms
counts
group Id
OG000
value
207
group Id
OG001
value
94
units
Participants
title
Blurred Vision, Severity, 4
categories
measurements
group Id
OG000
value
67
group Id
OG001
value
10
denoms
counts
group Id
OG000
value
207
group Id
OG001
value
94
units
Participants
title
Blurred Vision, Severity, 3+4
categories
measurements
group Id
OG000
value
167
group Id
OG001
value
63
denoms
counts
group Id
OG000
value
207
group Id
OG001
value
94
units
Participants
title
Blurred Vision, Severity, Any Scale >0
categories
measurements
group Id
OG000
value
14
group Id
OG001
value
7
denoms
counts
group Id
OG000
value
167
group Id
OG001
value
63
units
Participants
title
Blurred Vision, Interference, 0
categories
measurements
group Id
OG000
value
46
group Id
OG001
value
31
denoms
counts
group Id
OG000
value
167
group Id
OG001
value
63
units
Participants
title
Blurred Vision, Interference, 1
categories
measurements
group Id
OG000
value
38
group Id
OG001
value
15
denoms
counts
group Id
OG000
value
167
group Id
OG001
value
63
units
Participants
title
Blurred Vision, Interference, 2
categories
measurements
group Id
OG000
value
40
group Id
OG001
value
7
denoms
counts
group Id
OG000
value
167
group Id
OG001
value
63
units
Participants
title
Blurred Vision, Interference, 3
categories
measurements
group Id
OG000
value
29
group Id
OG001
value
3
denoms
counts
group Id
OG000
value
167
group Id
OG001
value
63
units
Participants
title
Blurred Vision, Interference, 4
denoms
counts
group Id
OG000
value
217
group Id
OG001
value
102
units
Participants
description
PRO-CTCAE is a patient-reported outcome measure developed to evaluate symptomatic toxicity in participants on cancer clinical trials. The PRO-CTCAE includes an item library of 124 items representing 78 symptomatic toxicities drawn from the CTCAE. It includes symptomatic toxicities drawn from the CTCAE like blurred vision, chills, constipation, decreased appetite, fatigue, general pain, mouth/throat sores, nausea, nosebleed, shortness of breath, vomiting, watery eyes, cough, itchy, loose/watery stools, Numb/Tingling Hands/Feet (N/T H/F), Pain/Burning (P/B) and Problems Tasting Food/Drink (Prob Tasting F/D) . Items are scored individually on a 0 to 4 scale for severity, frequency and interference. A score of 0 indicates no symptom or interference, while higher score of 4 signify increasing severity, frequency, and interference with daily activities.
groups
description
Participants with relapsed/refractory multiple myeloma (RRMM) received 30 minutes intravenous infusion of 2.5 milligram/kilogram (mg/kg) belantamab mafodotin on day 1 of each 21-day cycle
id
OG000
title
Belantamab Mafodotin
description
Participants with RRMM received 4 mg pomalidomide capsule daily on Days 1 to 21 of each 28-day cycle, along with 40 mg or at lower 20 mg (for participants \>75 years of age) dose of dexamethasone tablet once weekly (Days 1, 8, 15 and 22)
id
OG001
title
Pomalidomide Plus Dexamethasone
param Type
COUNT_OF_PARTICIPANTS
population Description
ITT Population. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified categories.
reporting Status
POSTED
time Frame
Up to approximately 263 weeks
title
Number of Participants With Symptomatic Adverse Effects as Measured by the Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Triangle